Evans syndrome future or investigational therapies
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Overview
Future or Investigational Therapies
Future or Investigational Therapies
In a patient with refractory disease, an allogeneic hematopoietic stem cell transplant (HSCT) resulted in complete clinical and serologic remission for more than 30 months. Allogeneic HSCT may be the only current curative therapy for Evans syndrome, but may also be complicated by significant toxicities. In more serious cases no cure exists.
References
References
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
